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Abstract 
Evidence suggests a physiological role of the GABA^ receptor in the pancreas. Clinically, an autoimmune reaction involving the GABA 
biosynthesizing enzyme, glutamic acid decarboxylase has been implicated in the development of insulin-dependent diabetes mettitus. To determine 
the subtypes of GABA^ receptor expressed in human pancreas, we analyzed, with the use of the reverse-transcription/polymerase ch in reaction 
technique human pancreatic tissue for the presence of GABAA receptor subunits ~1-6, ]/1-3, and 7/1-2 transcripts. Unlike brain tissue, pancreatic 
tissue only expresses the cz2, ]/3 and 7'1 subunits. Our results provide vidence of a specific GABAA receptor subtype xpressed in human pancreatic 
tissue. 
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1. ~u~on 
~,-Aminobutyric a id (GABA) is the major inhibitory 
neurotransmitter in the vertebrate central nervous ys- 
tem (CNS). It mediates its inhibitory action through a 
receptor complex, GABAA, that is a hetero-oligomeric 
protein composed of several distinct polypeptide sub- 
units [1]. In addition to GABA binding sites, the GABAA 
receptor also contains everal independent modulatory 
sites for therapeutic useful drugs such as benzodiazepi- 
nes, barbiturates and neuroactive steroids [2,3]. Molecu- 
lar cloning has identified at least 16 GABAA receptor 
subunits that can be grouped into several families (~-, 
fl-,7-,tL and p-) [4,5]. Functional expression of these sub- 
units in mammalian cell lines or Xenopus oocyte results 
in GABAA receptors with differential pharmacological 
characteristics [6,7]. The multiplicity of GABAA recep- 
tors expressed in the CNS provides one explanation for 
the complex pharmacology observed in brain homoge- 
nate [8,9]. 
In addition to the important role that GABA plays in 
the brain, the presence of GABA in nonneuronal organs 
has been demonstrated [10,11]. This suggests he involve- 
ment of GABA in the physiological functions o f  these 
nonneuronal tissues. However, the concentrations of
GABA in these tissues are generally low, about 1% of 
that in brain, with the exception of the female genital 
tract [12] and pancreatic slets [13]. In pancreatic slets, 
the GABA concentration is comparable to that of the 
CNS [14], however, it is still unclear why such a high 
concentration f GABA exists in the endocrine pancreas. 
In situ studies of GABA regulation of pancreatic 
hormone release have been controversial [15,16]. Re- 
cently though, the function and characterization f the 
GABA system in the pancreas has become a focus of 
interest as glutamic acid decarboxylase, a GABA biosyn- 
thesizing enzyme, is a dominant autoantigen i insulin- 
dependent diabetes mellitus [17]. This 65 kDa pancreatic 
fl cell protein is a target of an autoimmune r sponse in 
patients with this disease [18]. In pancreatic islet, evi- 
dence suggests GABA and insulin co-secretion from fl 
cell, but no GABA receptors were detected by [3H]- 
GABA binding in the fl cells[11]. A recent electrophysiol- 
ogical study revealed a GABA-triggered inhibitory hy- 
perpolarization and cessation of spiking activity in 
guinea-pig pancreatic ~ ceils [19]. The CI- dependent 
current elicited by GABA is completely and reversibly 
blocked by the GABAA receptor antagonist bicuculline. 
These results suggest that cz cells contain 
GABAAreceptors similar to those described in the CNS. 
However, it is not known whether human pancreas ex- 
presses a GABAA receptor or whether the subunits re- 
quired to form a functional GABAA receptor share the 
same diverse repertoire as seen in the CNS. With the use 
of 11 major GABAA receptor subunit-specific oligonu- 
cleotide pairs and reverse-transcription/polymerase 
chain reaction (RT/PCR) technique, we demonstrate 
that human pancreatic tissue expresses a limited popula- 
tion of the GABAA receptor subunits found in the CNS. 
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2. Materials and methods 
2.1. Isolation of human cortex total RNA 
Human cortex tissue was obtained from the Alzheimer's Disease 
Research Center at the University of Southern California nd the total 
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RNA was isolated using a single step phenol/phenol-chloroform 
method [20]. Human pancreas total RNA was purchased from Clon- 
tech (Palo Alto, CA). Prior to each experiment, aliquots of both RNA 
samples were centrifuged, rinsed with 70% ethanol and resuspended in 
sterile diethylpyrocarbonate (DEPC)-treated H20. 
2.2. Design of GABA a receptor subunit-specific oligonucleotide 
primers 
All the primers were localized to highly diverse regions of GABAA 
receptor family [5], the sense primer to the extracellular mino terminus 
domain and antisense primer to the large intracellular loop between 
putative transmembrane domains 3 and 4 (Fig. 1). All the primers 
(Table 1 and Fig. 1) used in the amplification were synthesized by 
Keystone Laboratories Inc. (Menlo Park, CA). 
2.3. Reverse transcription and PCR 
The reverse transcription reaction was prepared as previously de- 
scribed [21]. The first strand cDNA was synthesized from 1 mg of total 
RNA of human cortex or pancreas. Prior to the reaction, RNA samples 
were denatured at65°C for 5 min then quickly chilled. The reaction was 
carried out in a 30/gl mixture of the following: 40 units of recombinant 
M-MuLV reverse transcriptase with RNase H activity (Boehringer 
Mannheim, Indianapolis, IN), 10 units of human placental ribonu- 
clease inhibitor (BRL, Maryland), 50 mM Tris-HC1 (pH 8.3), 75 mM 
KC1, 3 mM MgCI2. 3 mM DTT, and 10 pmol of 12-18-mer oligo(dT) 
primer (Pharmacia, Piscataway, N J). The mixture was incubated at 
420C for 60 min and then heated at 65 °C for 5 min. One-tenth of the 
cDNA product was amplified in a Perkin-Elmer Cetus DNA Thermal 
Cycler (Norwalk, CT) in a final volume of 50/gl containing 50 mM KC1, 
10 mM Tris-HC1 (pH 8.3), 2.5 mM of each deoxynucleotide tri-
phosphate (dNTP), 20 pmol of each specific primer, 1.5 mM MgCI2, 
and 2.5 units ofAmpliTaq DNA polymerase (Perkin-Elmer Cetus). The 
PCR parameters were 94°C for 5 min, 55°C for 1 min and 72°C for 
1.5 min for the first cycle followed by 40 cycles of 940C for 1 min, 55°C 
for 1 min and 720C for 1.5 min, followed by an 8 min extention at 72°C. 
For the semiquantitative comparison of mRNA levels between cortex 
and pancreas, 10, 20, 30, 40, and 50 cycles were used instead of 40 
cycles. One fifth of each PCR product was electrophoretically separated 
on a 1% agarose gel (Seakem, FMC, Rockland, ME) containing ethid- 
ium bromide. 
2.4. Southern hybridization 
The PCR products eparated on the agarose gel were transferred to
a hybridization transfer membrane (Gene Screen Plus, NEN, DuPont) 
by capillary action in 0.4 N NaOH solution and neutralized in1 M Tris 
(pH 7.4), 1.5 M NaCI. The DNA was immobilized by UV-cross linking 
(Stratalinker, Stratagene, La Jolla, CA). The Southern hybridization 
was performed using 5' end labeled subunit-specific nternal primers 
(Table 2, Fig. 1). The pooled subunit specific oligonucleotide probes 
were 5' end-labeled in a 20 ml mixture containing 8 units of T4 polynu- 
cleotide kinase (Promega, WI), 50 mM Tris-HC1 (pH 7.5), 10 mM 
MgCI2, 5 mM DTT, 0.1 mM spermidine, and 50 mCi of [32p]ATP (3,000 
Ci/mmol, DuPont, NEN). The labeling reaction was carried out at 
37°C for 45 min followed by 68°C for 5 min to terminate he reaction. 
The blots were prehybridized for 1-2 h and then hybridized with 106 
dpm/ml probe in a 50% formamide, 5 x SSC solution at 37°C for 16 h 
before washing 2-3 times in 2 x SSC solution at 370C for 10 min, 
followed by exposure to XAR-5 Kodak film at -800C with an intensi- 
fying screen. 
2.5. Cloning of the PCR product and sequencing 
The PCR product of a4 from brain and ~2, t3 and Y1 from pancreas 
were run on a 0.7% low melting point agarose gel (GIBCO BRL, 
Gaithersburg, MD) and bands isolated. The isolated PCR products 
were subeloned into pCR II vector following the InVitrogen pCR II 
vector cloning protocol (InVitrogen, La Jolla, CA). The brain ct4 and 
pancreatic ct2, t3 and y1 were sequenced on both strands by dideoxy 
chain termination (Sequenase II, USB) [22]. 
In the control experiment for cDNA or chromosomal DNA contam- 
ination of the total RNA, 500 ng of DNase free, RNase (BMB, Indian- 
apolis, IN) was used in a mixture containing 1mg total RNA from 
either human cortex or human pancreas. The treatment was carried out 
at 37°C for 30 min before or after a reverse-transcription reaction. The 
mixture then prepared for PCR as above. 
I II IH IV 
17VID [] 
{x 4-2 ct (1-3)-2, (5-6)-2 ct (1-6)-3 ct (1-6)-I 
13 2-2 13 1-2, 13 3-2 I~ (1-3)-3 I~ (1-3)-1 
7(1-2)-2 y (1-2)-3 y (1-2)-1 
Fig. 1. Diagram of all the oligonucleotide primer locations. Box I to box 
IV indicate the four putative transmembrane domains. The arrows 
show the orientation of the PCR amplification. 
3. Results 
Based on the expected size of the PCR amplification 
product, all 11 GABAnreceptor subunit  ranscripts (0~1- 
6, i l l -3 ,  and 7/1-2 ) were detected in the human cortex 
(Fig. 2B,D). The human ~4 subunit  has not been cloned, 
but the size of PCR product corresponds to that expected 
from the bovine sequence. Therefore, the PCR product 
from brain total RNA amplified from the ~4 specific 
primers was subcloned and sequenced. The result was a 
95% homology to bovine ct4 cDNA in nucleotide se- 
quence and 93% in amino acid sequence within the am- 
plified region (data not shown) suggesting that human ~4 
GABAA receptor subunit  was amplified by these prim- 
ers. 
Using the same approach applied to human pancreas, 
only ~2,/~3 and 71 PCR products were detected (Fig. 
2A,C ) even when the PCR cycle number  was increased 
to 50. 
The nucleotide sequence of the PCR products of the 
human pancreas ~2, t3  and y l  was further determined 
and found to be identical to that of human brain subunits 
(data not shown). 
In order to exclude the possibility that the PCR ampli- 
fication of human pancreas RNA arose from chromoso- 
mal DNA or laboratory cDNA contaminat ion,  a control 
experiment was performed using RNase A digestion of 
the human pancreas and human cortex total RNA sam- 
ples before or after the reverse-transcription sy thesis of 
first strand cDNA. Aliquots were then amplified as 
above with either ~2 or t3  specific primers and visualized 
by ethidium bromide staining (Fig. 3). The results show 
that if the RNase A digestion was carried out before the 
reverse transcription, o c~2 and t3  product was ampli- 
fied. For  samples treated with RNase A after the reverse 
transcription the correct ~2 and t3  products were ampli- 
fied. This indicated that the first-strand cDNA template 
was indeed derived from its corresponding RNA tran- 
script. 
4. Discussion 
It is well documented that the concentrat ion f GABA 
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in pancreatic islet is comparable to that in the CNS [14] 
and that pancreaticfl-cells possess the enzymes necessary 
for GABA synthesis and degradation [23]. In the isolated 
perfused pancreas [24], or cultured islets [25], exogenous 
GABA and muscimol (a GABA receptor agonist) sup- 
pressed somatostatin release with no effect on insulin 
secretion. Although GABA was found to have no effect 
on insulin release in normal rats, small amounts of soma- 
tostatin (50 mg/h/i.v.) could regulate, moderately, basal 
insulin and glucagon levels in partial hypoinsulinemic 
humans resulting in a significant change in blood glucose 
concentration i  blood [26]. If GABA was released from 
fl-cells and acted as a modulator of somatostatin, its 
action would probably be mediated by specific receptors 
located on the target cells. However, the GABA receptor 
has not been characterized in the islet even though pre- 
liminary studies revealed [3H]GABA binding sites on 
peripheral cells of islet [27]. A recent investigation [19] 
using patch-clamp electrophysiological techniques ug- 
gests that GABA may mediate part of the inhibitory 
action of glucose on glucagon secretion by activating 
GABAA receptors in ~ cells of the islets, since the inward 
C1- current riggered by GABA and the effect of GABA 
on glucagon secretion can be abolished by bicuculline (a 
GABAA receptor antagonist). However, it is not known 
whether the GABAA receptor also exist in human tissue. 
Furthermore, the molecular nature of this putative 
GABAA receptor in pancreas would be of interest if it 
does exist. Using 11 sets of GABAA receptor subunit 
specific primers and the technique of reverse transcrip- 
tion/PCR, we show here that unlike brain tissue, only 
one specific variant of each subunit of the GABAA recep- 
tor transcript is expressed in human pancreatic tissue in 
a similar amount, but at a concentration much less than 
that found in brain. The relative low concentration of 
transcrips detected isconsistent with a low percentage of
pancreatic ells expressing GABAA receptors. None of 
the other 8 subunits were observed in pancreas even 
using 20 cycles beyond what was necessary for amplifica- 
tion, indicating that if they were expressed there, the 
concentration would be 22° or one million times less than 
in the brain. This result supports the existence of 
GABAA receptors in human pancreas and suggests that 
the likely subunit composition of the GABAA receptor 
in pancreas may be cz2f1371. 
To date, as many as 16 GABAA receptor subunits have 
been cloned. However, the eleven human subunits tested 
probably represent the majority of the GABAA receptor 
subunits found in the brain based on the in situ hybridi- 
zation of 13 GABAA receptor subunits in rodent CNS 
[28]. Among the 5 subunits not tested, pl and p2 are 
primarily expressed in the retina [29] whereas gene prod- 
ucts corresponding tof14, t$ and 73 subunits have not yet 
been identified in human brain. 
Our result of pancreatic expression of 3 known 
GABAA receptor subunits could not exclude the possibil- 
ity of other unknown subunit expressed in this tissue. To 
address the question, we have used a pair of universal 
Table 1 
Human GABAA receptor subunit-specitic oligonucleotides u ed in the PCR to identify the GABAA receptor subunit expression in human 
pancreas 
Subunit Size Cop) Name Sequence 5' ~ 3' Reference 
Hot- 1 470 ~tl-1 1,351 caaattaggggtgtagctggttgctgttgg 1,322 [34] 
ctl-2 881 caaacagt(a,t)gactctggaattgt 903 
H~t-2 440 ct2-1 1 ,148 tgcataagcgttgttctgtatcat 1,125 (**) 
ct2-2 708 ggceaatcaatcggaaaggagaca 731 
Hot-3 596 ct3-1 365 ggtctcagtcgggctgtcctgcac 1,342 (**) 
ct3-2 769 catgttgttgggacagagataatc 792 
Hcz-4 1,354(,) ct4-1 gatatggtttcagctgcattg [36] 
~t4-2 20 ggcatgttgcaaagatggtttctg 43 
Hot-5 462 ~t5-1 1 ,434 agttgtaaaagcgtttgttgac 1,414 (**) 
¢z5-2 973 cacctgatggggcagacggtg 993 
Hot-6 471 ~t6-1 1 ,127 agatgatatttggagtcagg 1,107 (**) 
ct6-2 664 tagtgagacaattaaatctaac 686 
Hfl-1 609 ill-1 1 ,278 gcgcccgtaggcctcgcggctgctcagggg 1,250 [34] 
ill-2 669 attgt(c,t)gactacaagatggtgtc 691 
I-Ifl-2 1,170 f12-1 1 ,325 taagatgttctcatgggggtccat 1,302 (**) 
fl2-2 160 ctgggcagactaagttggatctcc 183 
Hfl-3 790 f13-1 1 ,114 gaacggtcattctttgcettggc 1,092 (***) 
fl3-2 324 tattggagagataaaaggctcg 345 
HT-1 466 71-1 1,307 atct ctt gcggcacagaaat 1,287 (***) 
71-2 842 ctcaactgaaatcactcacacg 863 
H7-2 536 72-1 1 ,507 tcetgttcgacaatcttcaaaacagcagaa 1,478 (***) 
72-2 971 c(c,t)gaagtagtgaagacaact tc 993 
(*) The size of human g-4 PCR product is based on the bovine g-4 sequence data. 
(**) International patent application published under the patent cooperation treaty, number: PCT/GB92/01031. 
(***) Personal communication from Dr. Dolan B. Pritchett. 
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Fig. 2. PCR amplification product of human pancreas (A,C) and haman cortex (B,D). The products amplified from each pair of subunit specific 
primers (see Fig. 1 and Table 1) in EtBr-containing a arose gel (A,B) and Southern hybridization a alysis of the corresponding gel(C,D) using 
32P-labeled subunit specific internal primers (see Fig. 1 and Table 2). 
primers generated from transmembrane domain 2 and 4 
(TM2 and TM4) under a low stringency PCR condition 
(37°C for first 5 cycles and 42°C for 35 cycles). The PCR 
products ranged from 400 to 700 bp in size were isolated 
from a low melting agarose gel and subcloned into 
pCRII vector. About 200 individual clones were South- 
ern hybridized with 32p-labeled human ~2 and r3  primers 
located between TM2 and TM4 and about 20 clones 
showed a weak signal were sequenced. The result indi- 
cated that none of these 20 clones indicative of potential 
novel GABAA receptor subunit (data not shown). Thus 
we concluded that either no additional GABAA receptor 
subunit expressed in this tissue or the expression level 
was under the detection. 
Functional expression of various combinations of 
GABAA receptor subunits has resulted in GABAA recep- 
tors with distinct pharmacological properties. Expres- 
sion of different ~ subunit (~1 vs. 0c2 or cz3) co-expressed 
withfll and 9'2 exhibit ype I and type II benzodiazepine 
receptor pharmacology, respectively [6]. It has also been 
W. Yang et al. IFEBS Letters 346 (1994) 257-262 
1234567 8910U121314 
261 
Ha-2 • 
(440bp) 
4 Hb-3 
(401bp) 
Fig. 3. Contamination control of PCR amplification of ~t2 andfl3 subfragments. RNase treatment a 37°C for 30 min. Lanes I and 14: DNA molecular 
weight marker, Lanes 2-7: PCR amplification by ct2 primers. 2 and 5: RNase treated cortex or pancreas total RNA before, or 3 and 6 after 
reverse-transcription. 4 and 7: no RNase treatment. Lanes 8-13: PCR amplification byfl3 primers. 8 and 11: RNase treated cortex or pancreas total 
RNA before, or 9 and 12 after reverse-transcription. 10 and 13: no RNase treatment. 
reported that differing 7-subunits confer various sensi- 
tivities to benzodiazepines influencing both the affinity 
and efficacy of various benzodiazepine site ligands as 
functional modulators of GABAA receptors. Benzodiaz- 
epines potentiated GABA effects on receptor complexes 
containing T2 subunits much greater than these contain- 
ing T1 subunits [30,31]. Moreover, fl-carbolines such as 
methyl-6,7-dimethoxy-4-ethyl-fl-carboline-3-carboxylate 
(DMCM) and methyl-fl-carboline-3-carboxylate (fl-CCM) 
act as negative GABAA receptor modulators in recombi- 
nants containing ~1(~2) fll and 72 subunits but act as 
positive modulators at 0flfll?l and ~2fll?l receptors 
[32]. Thus compared to the 7/2 subunit, the ?1 subunit 
has been demonstrated to provide a unique pharma- 
cological profile relative to benzodiazepine modulation 
of the GABAA receptor complex. In human pancreas, we 
have found T1 but not T2 co-expressed with 0~2 and f13 
subunits. Even though the actual functional role of y 1- 
containing GABAA receptors in vivo is not known, the 
unique pharmacology compared to other 7/subunits may 
be significant in developing drugs that specifically modu- 
late GABAA receptors in the pancreas. 
Table 2 
Internal oligonucleotides of the GABAA receptor subunit-specific PCR 
product used as probe in Southern hybridization analysis 
Name Sequence 5' ~ 3' Ref. 
Hgl-3 1,246 ccatgcataacctctcttagtg 1,225 [34] 
H~2-3 1,103 cttgtcatttactacactcttccc 1,079 (**) 
Hot3-3 1,170 cttcatctccagggcctctgg 1,150 (**) 
Hc~4-3  gaagattcttgaacaactgtgg (.) 
H~5-3 1,386 cttgatcttggctgcttccaa 1,366 (**) 
H~6-3 1,022 cgccttctgtgtctgaagatt 1,002 (**) 
I-Ifl 1-3 1,218 gagtacatggtggccttggg 1,199 [34] 
I-Ifl2-3 1,265 actggcagccttctcagctgc 1,245 (**) 
Hf13-3 725 gacaacattcctcgagaccagacggtgctc 696 (***) 
H~,l-3 1,277 tggaatcagagtggatccagg 1,257 (***) 
H72-3 1,459 gccgtccagacactcatagcc 1,439 (***) 
(.) The sequence was obtained from sequencing data of partial cDNA 
cloned by the authors. 
(**) International patent application published under the patent coop- 
eration treaty, number: PCT/GB92/01031. 
(***) Personal communication from Dr. Dolan B. Pritchett. 
Based on electrophysiological studies, Roseman et al., 
[19] proposed that glucose inhibition of glucagon secre- 
tion may involve the co-secretion of GABA and insulin 
from fl cells. Under normal conditions where insulin se- 
cretion is stimulated, glucagon release will be inhibited 
by the co-secreted GABA. Accordingly, they predict hat 
a hypersecretion f glucagon would occur under condi- 
tions of fl-cell function impairment. Recent functional 
identification ofa GABA system in pancreatic tissue has 
focused considerable attention on the GABA-synthesiz- 
ing enzyme GAD. The evidence accumulated suggested 
that GAD in pancreatic fl cell, a dominant autoantigen 
served a major target of autoantibody associated with 
the development of insulin-dependent diabetes mellitus 
(IDDM) [33]. The cell-specific destruction offl cell in the 
patient of IDDM by autoimmune mechanisms would 
possibly provide a consideration of new regulation of 
glucose by other hormone systems such as glucagon. The 
current finding of a specific set of the GABAA receptor 
subunit ranscripts, possibly a functional receptor com- 
plex expressed in human pancreas provides an opportu- 
nity for the development of therapeutically useful drugs 
interacting with this GABAA recpetor for regulating the 
secretion of glucagon. 
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